Pioneering a Safer, More Advanced Aesthetic Medicine
At The Forefront Of Innovation Since 2003
Celebrating our milestones in aesthetic medicine, our timeline reflects Teoxane's dedication to evolving the industry and enhancing safety through clinical excellence and medical education. Discover how our consistent efforts have contributed to industry advancements for the sake of patients and practitioners alike.
Mrs. Valérie Taupin founds Teoxane Laboratories in Geneva, Switzerland.
Amidst the new emerging market of hyaluronic acid-based filling products.
TEOSYAL® ULTRA DEEP1, the 1st Volumizer to be injected with a fine needle.** & TEOSYAL KISS®, the 1st hyaluronic acid filler dedicated to lips2**
Creation of Teoxane Dermocosmetics3
The first to evolved crosslinked hyaluronic acid similar to dermal-fillers into a dermocosmetics portfolio as an at-home skincare solution.4
Launch of Teosyal® PURESENSE Redensity 2
The first and only company in the world to create a dermal filler designed specifically for the sensitive and delicate Tear Trough area. 5-7
Launch of Teosyal® PURESENSE Redensity 18
A unique “beauty booster”.9
Launch of our groundbreaking TEOSYAL RHA® line
The first range of HA dermal fillers that moves with and adapts to our facial expressions, for a more natural look and feel. 10
Approval by the FDA of RHA® 2, RHA® 3, RHA® 4
The first and only FDA- approved hyaluronic-based fillers for dynamic wrinkles and folds. 11
Opening of the Teoxane Academy in Geneva
Launch of the Lip Unique Collection
The first entire collection of 5 products suitable for treatment of the lips, because we know that every smile is unique.
Creation of Teoxane’s signature “ATP” approach
The first brand systematic medical approach grounded on the philosophy of “facial anatomy”,” techniques” and “science of products” to deliver best-in-class and evidence-based education & treatments in order to individualize the assessment of the face.12
Approval by the FDA of RHA® Redensity
U.S. FDA approval for RHA® Redensity’s first indication, which is for the treatment of moderate to severe dynamic perioral rhytids (lip lines) in adults aged 22 or older.
Multi Layering Technique
Teoxane's ground-breaking awarded technique that provides structural support and soft, dynamic volume enhancement. MLT has been developed to support practitioners and patients' need for customized treatments that respect facial dynamism, empowering individual beauty through natural-looking results.
30 million syringes sold worldwide13
Teoxane Achieves MDR Certification for TEOSYAL® PureSense and TEOSYAL RHA®
Multi Layering Technique 3.1
Designed upon Teoxane's Multi Layering Technique, Teoxane' signature MLT 3.1 offers the possibility to combine skin quality treatments with deeper support and dynamic volumization, to address the consequences of aging across the skin’s three layers. By harnessing Teoxane' skin boosting solutions, MLT 3.1 protocol helps improve skin quality while addressing volume loss, delivering optimal aesthetic results in just one session, with minimal product usage.
FDA approval for the Teoxane RHA® Collection with Mepivacaine
Teoxane and Revance Aesthetics receive FDA approval for the Teoxane RHA® Collection with Mepivacaine, marking the first major anesthetic innovation in hyaluronic acid fillers in nearly 20 years. Backed by over 60 years of medical use, Mepivacaine features the same mechanism of action as lidocaine, with less local vasodilation, reducing the potential for injection site reactions such as bruising, enhancing patient comfort.
Teoxane Opens Regional Office in Dubai
Teoxane has expanded its global footprint with the opening of a new regional office in Dubai, reinforcing our commitment to serving the Middle East and surrounding regions with greater proximity and support. This strategic presence strengthens collaboration with partners, enhances service to healthcare professionals, and accelerates the deployment of our innovation-driven portfolio across a fast-growing market. The new office marks an important step in bringing Teoxane’s expertise in hyaluronic acid science closer to the communities we serve.
RHA®4 with Mepivacaine Receives FDA Approval for Midface Augmentation
Teoxane celebrated a key scientific milestone with FDA approval of RHA®4 for midface augmentation, recognizing published clinical evidence of its safety, biocompatibility and natural integration into facial tissue. This validation also confirmed our Multilayering Technique (MLT) as an effective approach to restoring midface volume while preserving expressive, dynamic results.
Teoxane Introduces RHA® Kiss Volume
Teoxane announces the launch of RHA® Kiss Volume, a new dynamic HA gel designed to refine lip shape and bring balanced volume while preserving natural expression. This addition strengthens our lip portfolio and supports practitioners seeking precise, reliable results.
Teoxane Establishes New Subsidiary in Thailand
Teoxane has strengthened its global reach with the creation of a new subsidiary in Thailand, marking a significant step in our expansion across Asia. This local presence allows us to better support healthcare professionals, respond more closely to market needs, and bring our science-led portfolio to a rapidly growing aesthetic community. The Thai subsidiary reinforces Teoxane’s long-term commitment to delivering high-quality, trusted solutions to patients in the region.
Teoxane Reaches 40 Million Syringes Sold
Teoxane has achieved an important milestone with 40 million syringes sold worldwide, a testament to the trust placed in our science, quality and commitment to natural-looking results. This achievement reflects the dedication of our teams, the expertise of healthcare professionals who choose our products every day, and the confidence of millions of patients around the world.
